| Interventions |
For the main study randomised comparison, patients will randomised using a minimisation program (developed by the CRCTU) in a 1:1 ratio. Patients will be randomised to receive: Arm 1: Pfizer SARS-CoV2 Vaccine Arm 2: Moderna SARS-CoV2 Vaccine For the sub-study randomised comparison, patients will be randomised using a minimisation program in a 1:1:1 ratio. Patients will be randomised to receive: Arm 1: Pfizer SARS-CoV2 Vaccine Arm 2: Moderna SARS-CoV2 Vaccine Arm 3: Novavax SARS-CoV2 Vaccine The dose of Pfizer vaccine is 30 mg contained in 0.3 ml of the diluted vaccine given intramuscularly. The dose of Moderna vaccine is 0.5 ml, containing 100 micrograms of messenger RNA (mRNA), given intramuscularly. The dose of Novovax vaccine is 5 mg recombinant spike protein with 50 mg Matrix-M1 adjuvant (0.5 ml). A dose of 5 mg recombinant spike protein with 50 mg Matrix-M1 adjuvant (0.5 ml) will be given intramuscularly. Where possible participants will be followed up in accordance with standard clinical practice for the relevant disease cohort and data will be collected retrospectively from clinic records 3 months after re-boost vaccination. Where participants do not attend for a routine clinic visit, data may be collected following an additional telephone follow-up call. |